Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice
- 423 Downloads
Cytisine (CYT) is a partial agonist of brain α4β2 nicotinic acetylcholine receptors widely used in Central/Eastern Europe for smoking cessation.
This study evaluated the effect of CYT on the ability of classical and novel antiepileptic drugs to prevent seizures evoked by the 6-Hz test, a model of psychomotor seizures in mice thought as a model of drug-resistant seizures.
CYT administered intraperitoneally (i.p.) in a dose of 2 mg kg−1 significantly inhibited the anticonvulsant activity of lacosamide, levetiracetam, and pregabalin, increasing their median effective doses 50 (ED50) values from 6.88 to 10.52 mg kg−1 (P < 0.05) for lacosamide, from 22.08 to 38.26 mg kg−1 (P < 0.05) for levetiracetam, and from 40.48 to 64.61 mg kg−1 (P < 0.01) for pregabalin, respectively. There were no significant changes in total brain concentrations of lacosamide, levetiracetam, and pregabalin following CYT i.p. administration. CYT administered in a dose of 2 mg kg−1 failed to change the protective action of clobazam, clonazepam, phenobarbital, tiagabine, and valproate in the 6-Hz test. Neither CYT (2 mg kg−1) alone nor its combination with the anticonvulsant drugs (at their ED50 values from the 6-Hz test) affected motor coordination; skeletal muscular strength and long-term memory, as determined in the chimney; and grip strength and passive avoidance tests, respectively.
CYT-evoked alterations in the protection provided by some antiepileptic drugs against seizures can be of serious concern for epileptic smokers, who might demonstrate therapeutic failure to lacosamide, levetiracetam, and pregabalin, resulting in possible breakthrough seizure attacks.
KeywordsCytisine Epilepsy Psychomotor seizures Smoking cessation
This study was supported by a research grant from the University of Rzeszów (Rzeszów, Poland) (DS/2014, DS/2015). The authors express their thanks to Dr. G. Raszewski (Institute of Rural Health, Lublin, Poland) for the skillful determination of the brain concentrations of antiepileptic drugs.
Compliance with ethical standards
The experimental procedures listed were approved by the Second Local Ethics Committee at the University of Life Sciences in Lublin (license nos. 88/2012 and 61/2014) and conformed to the Guide for the Care and Use of Laboratory Animals.
Conflict of interest
Prof. P Tutka has undertaken paid consultancy for Aflofarm, a manufacturer of CYT. Prof. JJ Luszczki has been involved in the design and development of new antiepileptics and CNS drugs. Additionally, within the last 5 years, he has received an unrestricted research grant from GlaxoSmithKline (Brentford, UK). The remaining authors have no conflicts of interest to disclose.
- Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280:346–356PubMedGoogle Scholar
- Florek-Luszczki M, Wlaz A, Kondrat-Wrobel MW, Tutka P, Luszczki JJ (2014a) Effects of WIN 55, 212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. J Neural Transm (Vienna) 121:707–715CrossRefGoogle Scholar
- Florek-Luszczki M, Wlaz A, Zagaja M, Andres-Mach M, Kondrat-Wrobel MW, Luszczki JJ (2015) Effects of WIN 55, 212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. Pharmacol Biochem Behav 130:53–58CrossRefPubMedGoogle Scholar
- Reagan-Shaw S, Nihal M, Ahmad N (2007) Dose translation from animal to human studies revisited. The FASEB Journal 22 (3):659–661Google Scholar
- Stoyanov S, Yanachkova M (1972) Tabex – therapeutic efficacy and tolerance (in Bulgarian). Savr Med 23:30–33Google Scholar
- Tutka, P., Wahl, H., Dąbrowa, M., Błażej, J., 2016. Cytisine as an effective treatment for nicotine addiction in Poland: 50 years of experience. In: 2016 Annual Meeting of the Society for Research on Nicotine and Tobacco. Chicago, 125.Google Scholar
- WHO Report on the Global Tobacco Epidemic, 2013, 12. http://apps.who.int/iris/bitstream/10665/85380/1/9789241505871_eng.pdf?ua=1 [last accessed 10 February 2016].
- Xi ZX (2010) Preclinical pharmacology, efficacy and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug Health Patient Saf 2010:39–48Google Scholar
- Zatoński W, Sulkowska U, Przewoźniak K, Zatoński M (2014) Malignant cancer epidemiology in Poland. In: Potrykowska A, Strzelecki Z, Szymborski J, Witkowski J (eds) Cancer incidence and mortality versus the demographic situation in Poland. Governmental Population Council, Warsaw, pp. 30–49 (In Polish)Google Scholar